BR9803486A - Derivados de imidazolidina, sua preparação, seu uso e preparações farmacêuticas compreendendo os mesmos - Google Patents

Derivados de imidazolidina, sua preparação, seu uso e preparações farmacêuticas compreendendo os mesmos

Info

Publication number
BR9803486A
BR9803486A BR9803486-3A BR9803486A BR9803486A BR 9803486 A BR9803486 A BR 9803486A BR 9803486 A BR9803486 A BR 9803486A BR 9803486 A BR9803486 A BR 9803486A
Authority
BR
Brazil
Prior art keywords
formula
compounds
pharmaceutical preparations
prophylaxis
therapy
Prior art date
Application number
BR9803486-3A
Other languages
English (en)
Inventor
Volkmar Dr Wehner
Wolfgang Schmidt
Dirk Seiffge
Hans Ulrich Dr Stilz
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9803486A publication Critical patent/BR9803486A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Patente de Invenção: <B>"DERIVADOS DE IMIDAZOLIDINA, SUA PREPARAçãO, SEU USO E PREPARAçõES FARMACêUTICAS COMPREENDENDO OS MESMOS"<D>. A presente invenção refere-se a novos derivados de imidazolidina da fórmula I, onde B, E, W, Z, R, R^ 0^, R², R³ <MU>e<MV> e h possuem os significados indicados a seguir. Os compostos da fórmula I são compostos farmacêuticos ativos e valiosos que são apropriados, por exemplo, para terapia e profilaxia de distúrbios inflamatórios, por exemplo, artrite reumatóide ou de distúrbios alérgicos. Os compostos da fórmula I são inibidores da adesão e migração de leucócitos e/ou antagonistas do receptor de adesão VLA-4 pertencendo ao grupo das integrinas. Elas são geralmente apropriadas para terapia ou profilaxia de doenças que são causadas pela extensão indesejável da adesão de leucócitos e/ou migração de leucócitos ou estão associadas às mesmas, ou onde tomam parte as interações de célula-célula ou célula-matriz que baseiam-se nas interações dos receptores VLA-4 com seus ligantes. A invenção refere-se, adicionalmente, a processos para preparação dos compostos da fórmula I, seu uso na terapia e profilaxia de estados de doença mencionados e preparações farmacêuticas que contêm os compostos da fórmula I.
BR9803486-3A 1997-09-18 1998-09-17 Derivados de imidazolidina, sua preparação, seu uso e preparações farmacêuticas compreendendo os mesmos BR9803486A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19741235A DE19741235A1 (de) 1997-09-18 1997-09-18 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
BR9803486A true BR9803486A (pt) 2001-05-22

Family

ID=7842856

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9803486-3A BR9803486A (pt) 1997-09-18 1998-09-17 Derivados de imidazolidina, sua preparação, seu uso e preparações farmacêuticas compreendendo os mesmos

Country Status (26)

Country Link
US (2) US6423712B1 (pt)
EP (1) EP0903353B1 (pt)
JP (1) JP4537505B2 (pt)
KR (1) KR19990029915A (pt)
CN (1) CN1125054C (pt)
AR (1) AR015444A1 (pt)
AT (1) ATE449786T1 (pt)
AU (1) AU748599B2 (pt)
BR (1) BR9803486A (pt)
CA (1) CA2247551A1 (pt)
CZ (1) CZ298898A3 (pt)
DE (2) DE19741235A1 (pt)
HK (1) HK1019606A1 (pt)
HR (1) HRP980511A2 (pt)
HU (1) HUP9802121A3 (pt)
ID (1) ID20855A (pt)
IL (1) IL126247A0 (pt)
MY (1) MY121745A (pt)
NO (1) NO984309L (pt)
NZ (1) NZ331924A (pt)
PL (1) PL328686A1 (pt)
RU (1) RU2213737C2 (pt)
SK (1) SK124798A3 (pt)
TR (1) TR199801840A2 (pt)
TW (1) TW553937B (pt)
ZA (1) ZA988496B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL323130A1 (en) * 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19821483A1 (de) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
RO121640B1 (ro) * 1999-05-07 2008-01-30 Texas Biotechnology Corporation Derivaţi de acid propionic ce inhibă legarea integrinelor de receptorii acestora, compoziţie farmaceutică ce îi conţine şi utilizare a acesteia
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ2002518A3 (cs) * 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
CA2396087A1 (en) 1999-12-28 2001-07-19 Louis Stanley Chupak Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
FR2823209B1 (fr) * 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
DE10137595A1 (de) * 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
GEP20084406B (en) 2003-05-30 2008-06-25 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2012039132A1 (ja) * 2010-09-22 2012-03-29 三井化学アグロ株式会社 含フッ素カルバマート基を有するアミノ酸アミド誘導体の製造方法、その製造中間体、及びエチレンジアミン誘導体の製造方法
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (pt)
DE3044236A1 (de) 1980-11-25 1982-06-16 Hoechst Ag, 6000 Frankfurt Aminosaeurederivate und verfahren zu ihrer herstellung
DE2937779A1 (de) 1979-09-19 1981-04-09 Hoechst Ag, 6000 Frankfurt Aminosaeurederivate und verfahren zu ihrer herstellung
FR2487829A2 (fr) 1979-12-07 1982-02-05 Science Union & Cie Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4350704A (en) * 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
EP0278530A3 (de) 1980-08-30 1989-08-02 Hoechst Aktiengesellschaft Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
DE3038901A1 (de) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
EP0050800B2 (en) 1980-10-23 1995-06-07 Schering Corporation Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
US4374847A (en) * 1980-10-27 1983-02-22 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
CA1341296C (en) 1981-12-29 2001-09-25 Hansjorg Urbach 2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use
DE3210496A1 (de) 1982-03-23 1983-10-06 Hoechst Ag Neue derivate bicyclischer aminsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung
DE3211397A1 (de) 1982-03-27 1983-11-10 Hoechst Ag, 6230 Frankfurt Spiro (4.(3+n))-2-aza-3-carbonsaeure-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
DE3227055A1 (de) 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung
DE3242151A1 (de) 1982-11-13 1984-05-17 Hoechst Ag, 6230 Frankfurt Neue derivate tricyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung, sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung
DE3246503A1 (de) 1982-12-16 1984-06-20 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(5.3.0)-decan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3818850A1 (de) 1988-06-03 1989-12-07 Hoechst Ag Oligopeptide mit zyklischen prolin-analogen aminosaeuren
JPH02160581A (ja) * 1988-12-14 1990-06-20 Showa Denko Kk 感熱記録材用添加剤
DE4009506A1 (de) 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
US5242939A (en) * 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
DK0626861T4 (da) 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
EP0625912B1 (en) 1992-02-12 1997-04-16 Biogen, Inc. Treatment for inflammatory bowel disease
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
GR920100131A (el) * 1992-04-03 1993-12-30 Ntoural A V E E Systimata Epip Δισκοειδής κόμβος και εξαρτήματα συνδέσεως ράβδων για λυόμενες κατασκεύες.
DE4213634A1 (de) * 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
DE4308034A1 (de) * 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
ES2270425T3 (es) 1994-01-25 2007-04-01 Elan Pharmaceuticals, Inc. Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
CA2193828A1 (en) 1994-06-29 1996-01-11 Timothy P. Kogan Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
EP0801192B1 (en) * 1994-11-11 2005-01-26 Kabushiki Kaisha Tokai Rika Denki Seisakusho Method of registering identification code
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
EP0796855B1 (de) 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
SK8199A3 (en) 1996-07-25 2000-04-10 Biogen Inc Cell adhesion inhibitors, preparation method thereof and pharmaceutical composition with their content
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) * 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
HRP980511A2 (en) 1999-06-30
EP0903353B1 (de) 2009-11-25
DE59814412D1 (de) 2010-01-07
KR19990029915A (ko) 1999-04-26
ATE449786T1 (de) 2009-12-15
US20030125565A1 (en) 2003-07-03
AU748599B2 (en) 2002-06-06
ZA988496B (en) 1999-03-18
TW553937B (en) 2003-09-21
MY121745A (en) 2006-02-28
RU2213737C2 (ru) 2003-10-10
HUP9802121A2 (hu) 1999-06-28
US6759424B2 (en) 2004-07-06
JP4537505B2 (ja) 2010-09-01
DE19741235A1 (de) 1999-03-25
CA2247551A1 (en) 1999-03-18
CN1218047A (zh) 1999-06-02
CN1125054C (zh) 2003-10-22
ID20855A (id) 1999-03-18
TR199801840A3 (tr) 1999-04-21
NZ331924A (en) 2000-02-28
US6423712B1 (en) 2002-07-23
SK124798A3 (en) 1999-04-13
NO984309L (no) 1999-03-19
HUP9802121A3 (en) 1999-07-28
EP0903353A1 (de) 1999-03-24
TR199801840A2 (xx) 1999-04-21
NO984309D0 (no) 1998-09-17
CZ298898A3 (cs) 1999-04-14
JPH11158157A (ja) 1999-06-15
IL126247A0 (en) 1999-05-09
HK1019606A1 (en) 2000-02-18
PL328686A1 (en) 1999-03-29
AR015444A1 (es) 2001-05-02
AU8523198A (en) 1999-04-01

Similar Documents

Publication Publication Date Title
BR9803486A (pt) Derivados de imidazolidina, sua preparação, seu uso e preparações farmacêuticas compreendendo os mesmos
BR9804695A (pt) Derivados de imidazolidina substituìdos, sua preparação, sua aplicação de preparações farmacêuticas contendo os mesmos
BR9803969A (pt) Novos heterociclos de anel com cinco elementos, sua preparações seu uso e preparação farmacêuticas compreendendo os mesmos
Snyder et al. Prostaglandins modulate macrophage Ia expression
BR9705725A (pt) Heterociclos como inibidores da adesão de leucócitos e antagonistas de vla-4
DE59915127D1 (de) Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
Green et al. Aggregation of macrophages and fibroblasts is inhibited by a monoclonal antibody to the hyaluronate receptor
Valone et al. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma.
Breviario et al. IL-1-induced adhesion of polymorphonuclear leukocytes to cultured human endothelial cells. Role of platelet-activating factor.
Phonphok et al. Stabilization of clathrin coated vesicles by amantadine, tromantadine and other hydrophobic amines
Melmon et al. Separation of specific antibody-forming mouse cells by their adherence to insolubilized endogenous hormones
Tokumura et al. Structural analogs of alkylacetylglycerophosphocholine inhibitory behavior on platelet activation.
Kuna et al. IL-8 inhibits histamine release from human basophils induced by histamine-releasing factors, connective tissue activating peptide III, and IL-3.
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
BR0012610A (pt) Novo derivado de difenilpiperidina
AU3754489A (en) Inhibition of lipogenesis
Perez et al. Formyl peptide-induced chemotaxis of human polymorphonuclear leukocytes does not require either marked changes in cytosolic calcium or specific granule discharge. Role of formyl peptide receptor reexpression (or recycling).
De Chaffoy de Courcelles et al. Stimulation by serotonin of 40 kDa and 20 kDa protein phosphorylation in human platelets
Chow et al. Effect of protein depletion on plasma proteins in the dog measured by electrophoretic analysis
Valone et al. Enhanced human monocyte cytotoxicity by platelet-activating factor.
BR0011296A (pt) Derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos
BR0211535A (pt) Derivados de imidazolidina, sua preparação e seu uso como antagonistas de vla-4
Olsen et al. IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis
Fiedel et al. Modulation of platelet activation by native DNA
Czarnetzki et al. Saturated and unsaturated 1-O-alkyl-2-O-acetoyl-sn-glycero-3-phosphocholines derived from ratfish liver oil: Effect on human leukocyte migration

Legal Events

Date Code Title Description
TC Change of name
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36 DA LPI .